Abstract
The platinum drugs are widely used in cancer therapy. In recent years they have been successfully combined with the taxanes, especially for the treatment of patients with cancers of the ovary, lung, breast, and head and neck. This chapter presents some of the evidence on the use of platinum and taxane regimens in these malignancies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ovarian Cancer
Abu-Rustum, N. R., Aghajanian, C., Borakat, R. R., Fenelly, D., Shapiro, F., and Spriggs, D. (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 24(Suppl 15), S15–62—S15–67.
Advanced Ovarian Cancer Trialist Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303, 884–893.
Alberts, P. S., Green, S. Hannigan, E. V.,(1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III, randomized trial in stages III and IV ovarian cancer. J. Clin. Oncol. 10, 706–717.
Bella, M., Cocconi, G., and Lotticci, R. (1994) Mature results of a prospective randomized trial comparing two different dose-intensity regimens of cisplatin in advanced ovarian carcinoma. Ann. Oncol. 5 (Suppl 80), 2.
Bertelsen, K., Jakobsen, A., Stroyer, I., (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin and cisplatin in advanced epithelial ovarian cancer. A Danish Ovarian Study Group trial (DaCOVA). Gynecol. Oncol. 49, 30–35.
Blockledge, G., Lawton, F., Redman, C., and Kelly, K. (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br. J. Cancer 59, 650–653.
Bolis, G., Scarfone, G., Villa, A., Acerboni, S., Siliprandi, V., and Guarnerio (1997) A phase I trial with fixed dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Semin. Oncol. 24(Suppl 2), S2–23—S2–25.
Bookman, M. A., McGuire, W. P., Kilpatrick, D.,(1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14, 1895–1902.
Calvert, A. H. (1997) A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin. Oncol. 24(Suppl 2), S2–85-S2–90.
Calvert, A. H., Newell, D. R., Gumbrell, L. A.,(1989) Carboplatin dosage: evaluation of a simple formula based on renal function. J. Clin. Oncol. 7, 1748–1756.
Capri, G., Tarenzi, E., Fulfaro, F., and Gianni, L. (1996) The role of taxanes in the treatment of breast cancer. Semin. Oncol. 23 (Suppl 2), 68–75.
Chevallier, B. Fumoleau, P., Kerbrat, P.,(1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer. A phase II trial of the Clinical Screening Cooperative Group of the European Organisation for Research and Treatment of Cancer. J. Clin. Oncol. 13 314–322.
Donehower, R. C., Rowinsky, E. K., Grochow, L. K.,(1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat. Rep. 71, 1–7.
du Bois, A., Luck, H., Meier, W.,(1997) Carboplatin/paclitaxel versus cisplatin paclitaxel as first line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. Semin. Oncol. 24(Suppl 15), S15 44-S15–52.
Einzig, A. I., Wiernik, P. H., Sasloff, J.,(1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10, 1748–1753.
Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D.,(1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high dose versus low dose and long versus short infusion. J. Clin. Oncol. 12, 2654–2666.
Eisenhauer, E. A., Vermokken, J. B., and van Glabbeke, M. (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivarate analysis of 704 patients. Ann. Oncol. 8, 963–968.
Gelmon, K. (1994) The taxoids: paclitaxel and docetaxel. Lancet 344, 1267–1272.
Gianni, L., Kearns, C. M., Giani, A.,(1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol. 13, 180–190.
Gore, M. E. (1996) The role of taxanes, in Ovarian Cancer 4, Chapman & Hall Medical, London, pp. 143–152
Gore, M. E., Fryatt, I., Wiltshaw, E., and Dawson, T. (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207–211.
Gore, M. E., Levy, V., Rustin, G.,(1995) Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br. J. Cancer 72, 1016–1019.
Gore, M. E., Preston, N., and A’Hern, R. P. (1995) Platinum-taxol non-cross resistance in epithetial ovarian cancer. Br. J. Cancer 71, 1308–1310.
Greco, F. A. and Hainsworth, J. D. (1996) Paclitaxel via 1-hour infusion: rationale and pharmocology. Semin. Oncol. 23 (Suppl 15), 19–20.
Gruppo Interregionale Cooperativo Oncologica Ginecologica (1992) Long term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and Adriamycin in advanced ovarian cancer. Gynecol. Oncol. 45, 115–117.
Hakes, T., Hoskins, W., Jones, W.,(1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian cancer. Gynecol. Oncol. 45, 284–289.
Harper, P. (1997). ICON2 and ICON3 data in previously untreated ovarian cancer: results to date. Semin. Oncol. 24(Supp1.15), S15–23-S15–25.
Huizing, M. T., Van Warmerdam, L. J. C., Rosing, H.,(1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J. Clin. Oncol. 15, 1953–1964.
Kaye, S. B., Piccart M., Aapro, M., Francis, P. and Kavanagh, J. (1997) Phase II trials of docetaxel (Taxotere ®) in advanced ovarian cancer-an updated overview. Eur. J. Cancer. 33, 2167–2170.
Kaye, S. D., Lewis, C. R., Paul, J.,(1992) Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340, 329–333.
Lavelle, F., Bissery, M. C., Combeau, C.,(1995) Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol. 22 (Suppl 4), 3–16.
Mainwaring, P. N., and Gore, M. E. (1995) The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. Anticancer Drugs. 6 (Suppl 5), 29–41.
Markman, M. (1997) Current status and future directions of platinum/paditaxel-based chemotherapy of ovarian cancer. Semin. Oncol. 24(Suppl 11), S11–24-S11–27.
Markman, M., Rothman, R., Hakes, T.,(1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389–393.
McGuire, W. P., Hoskins, W. J., Brady, M. F.,(1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1–6.
Muggia, T. M., Brady, P. S., Braly, M. F.,(1997) Phase II of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage II and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study # 132. Proc. Am. Soc. Clin. Oncol. 16, 352a.
National Institutes of Health Consensus Development Conference Statement. (1994) Ovarian cancer: screening, treatment, and follow-up. Gynecol. Oncol. 55, S4–14
Neijt, J. P., Engelholm, S. A., Witteveen, P. 0.,(1997) Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysis. Semin. Oncol. 24(Suppl 15), S15–36-S15–39.
Ngan H., Choo Y., Cheung M.,(1989) A randomized study of high-dose versus low-dose cisplatin combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35, 221–227.
Olsen, J. K., Sood, A. K., Sorosky, J. I., Anderson, B., and Buller, R. E. (1998) Taxol hypersensitivity: rapid retreatment is safe and cost effective. Gynec. Oncol. 68, 25–28.
Ozols, R. F., Thigpen, J. T., Dauplat, J.,(1993) Dose Intensity. Ann. Oncol. 4 (Suppl 4), S49 - S56.
Piccart, M. J., Bertelsen, G., Stuart, G.,(1997) Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (OvCa)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc. Am. Soc. Clin. Oncol. 16, 352a.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P.,(1991) Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9, 1692–1703.
Rowinsky, E. K., and Donehower, R. C. (1995). Paclitaxel (Taxol) N. Engl. J. Med. 332, 1004–1014.
Siddiqui, N., Boddy, A. V., Thomas, H. D.,(1997) A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br. J. Cancer 75, 287–294.
Stuart, G., Bertelsen, K., Mangioni, C.,(1998) Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc. Am. Soc. Clin. Oncol. 17, 361a.
Swenerton, K., Jeffrey, J., Stuart, G.,(1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 10, 718–726.
ten Bokkel Huinink, W., Veenhof, C., Huizing, M.,(1997) Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin. Oncol. 24(Suppl 2), S2–21-S2–33.
ten Bokkel Huinink, W. W., Prove, A. M., Piccart, M.,(1994) A phase II trial with
docetaxel (Laxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol. 5, 527–532.
Thigpen, T., Blessing, J., Ball, H.,(1990) Phase II trial of taxol as second line therapy for ovarian carcinoma: a Gynecologic Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 9, 604.
Tom, V. (1997). Randomized study of cyclophosphamide, doxorubicin and cisplatin (CAP) vs single agent carboplatin in ovarian cancer patients requiring chemotherapy: interim results of ICON2. Proc. Am. Soc. Clin. Oncol. 15, 280.
Trimble, E. L., Adams, J. R, Vera, D.,(1993). Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Centre 9103. J. Clin. Oncol. 11, 2405–2410.
Trope, C. and Kristensen, G. (1997) Current status of chemotherapy in gynaecologic cancer. Semin. Oncol. 24(5 Suppl. 15), S15–1-S15–22.
Van Glabbeke, M., Vermorken, J., and Eisenhauer, E. (1997) Predictors of survival (OS) and time to progression (TTP) following second-or third-line treatment in advanced ovarian cancer (OVCA): an analysis of 714 patients (PTS) treated with paclitaxel, docetaxel or high dose epirubicin. Proc. Am. Soc. Clin. Oncol. 16, 354a.
Vermorken, J. B., ten Bokkel Huinink, W. W., Eisenhauer, E. A.,(1993) Carboplatin versus cisplatin. Ann. Oncol. 4 (Suppl 4), S41 - S48.
Wari, M. C., Taylor, H. L., Wall, M. E.,(1971) Plant anti-tumour agents VI. The isolation and structur of Taxol, a novel antileukemic and antitumour agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2329.
Lung Cancer
Androulakis, N., Kourousis, C., Kakolyris, S.,(1996) First line treatment of nonsmall-cell lung cancer with docetaxel and cisplatin. Preliminary results of a phase II study. Ann. Oncol. 7 (Suppl 5), 98–99.
Belani, C. R, Aisner, J., Hiponia, D.,(1995) Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 22 (Suppl 9), 7–12.
Belli, L., Le Chavalier, T., Gottfried, M.,(1995) Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14, 348.
Bonomi, R, Kim, C., Kugler, K., and Johnson, D. (1997) Results of a phase III trial comparing Taxol-cisplatin regimens to etoposide-cisplatin in non-small cell lung cancer. Lung Cancer 18 (Suppl 1), 10.
Bunn, P. A. and Kelly, K. (1995) A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center Study. Semin. Oncol. 22(suppl 9) 2–6.
Bunn, R. A. (1997) Defining the role of paclitaxel in lung cancer. Summary of recent studies and implications for future directions. Semin. Oncol. 24(Suppl 12), S12–15-S12–62.
Burris, H. Eckardt, J., Fields, S.,(1993) Phase II trials of taxotere in patients with non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12 335.
Carney, D. N. (1996) Chemotherapy in the management of patients with inoperable nonsmall-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 71–75.
Cole, J. T., Galla, R. J., Margues, C. B.,(1995) Phase I-II study of cisplatin and docetaxel (Taxotere) in non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14, 357.
Cole, J. T., Galla, R. J., Rittenberg, C. N.,(1997) Defining the dose of docetaxel (Taxotere) in combination chemotherapy of non-small-cell lung cancer: preserving efficacy with lower dose regimens. Proc. Am. Soc. Clin. Oncol. 16 465a.
Creaven, P. J., Raghavan, D., Perez, R. P.,(1996) Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors. Semin. Oncol. 23 (Suppl 16), 26–31.
De Vore, R. F. III. Jagasia, M., Johnson, D. H. (1997) Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer. Preliminary results comparing sequential phase II trieals. Semin. Oncol. 24(Suppl 12) 512–27-S12–29.
Douillard, F. U., Monnier, A., Ibrahim, N., (1995) Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSLLC). Proc. Am. Soc. Clin. Oncol. 14, 351.
Ellis, R. A., Smith, I. C., Hardy, J. R.,(1995) Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br. J. Cancer 71, 366–370.
Fossella, F. V., Lee, J. S., Shin, D. M.,(1995) Phase II study of docetaxel for advanced or metastatic platinum refractory non small cell lung cancer. J. Clin. Oncol. 13, 643–651.
Georgiadis, M. S., Schuler, B. S., Brown, J. E.,(1997) Paclitaxel by 96-hour continuous infusion in combination with cisplatin. A phase I trial in patients with advanced lung cancer. J. Clin. Oncol. 15, 735–743.
Giaccone. G., Postmus, R, Debruyne, C., for the EORTC LCCG (1997) Final results of an EORTC phase III study of paclitaxel versus teniposide in combination with cisplatin in advanced NSCLC. Proc. Am. Soc. Clin. Oncol. 16, 460a.
Greco F. A., Hainsworth, J. D. (1997) Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin. Oncol. 24(Suppl 12), S12–14-S12–17.
Huizing, M. T., Giaccone, G., van Wormerdam, L. J. C.,(1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer.
Jaakkimainen, L., Goodwin, P. J., Pater, J.,(1990) Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J. Clin. Oncol. 8, 1301–1309.
Klastersky, J., Sculier, J. P., European Lung Cancer Working Party (1995) Dose finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small-cell lung cancer. Lung Cancer 12, 117–125.
Kosimidis, P., Mylonakis, N., Fountzilas, G., Samantos, C., Athonasiodis, A., and Skarlos, P., (1996) Paclitaxel and Carboplatin in inoperable non-small-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 68–70.
Langer, C. J., Millenson, M., Rosvold E.,(1997) Paclitaxel (1 hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and its network. Semin. Oncol. 24(Suppl 12), S12–81-S12–88.
Miller, V. A, Rigas, J. R, Francis, P. A,(1995) Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75, 968–972.
Natale, R. B. (1996) Preliminary results of a phase VII clinical trial of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 23 (Suppl 16), 51–54.
Non-Small Cell Lung Cancer Collaborative Group. (1995) Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311, 899–909.
Paesmans, M., Sculier, J. P., Libert R,For the European Lung Cancer Working Party (1996) Prognostic factors for survival in advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J. Clin. Oncol. 13, 1221–1230.
Pirker, R., Kraynik, G., Zochbauer, S., Malarjeri, R., Kneussel, M., and Huber, H. (1995) Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 6, 833–835.
Ramanathan, R. K., and Belani, C. P. (1997) Chemotherapy for advanced non-small cell lung cancer: past, present and future Semin. Oncol. 24, 440–454.
Rowinsky, E. K., Flood, W. A., Santorius, S. L.,(1995) Phase I study of paclitaxel as a 3 hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin. Oncol. 22 (Suppl 9), 48–54.
Rowinsky, E. K., Chaudhry, V., Forastiere, A. A., (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J. Clin. Oncol. 11, 2010–2020.
Souquet, P. J., Chauvin, F., Boissell, J. P.,(1993) Polychemotherapy in advanced non-small cell lung cancer: a metaanalysis. Lancet 342, 19–21.
von Pawel, J., Wagner, H., Niederle, N.,(1996) Phase II study of paclitaxel and cisplatin in patients with non-small-cell lung cancer. Semin. Oncol. 23 (Suppl 16), 47–50.
Zalcberg, J. R., Bishop, J. F., Millward, M.J.,(1995) Interim results of a phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Eur. J. Cancer, 3A(Suppl 5), 1084.
Head and Neck Cancer
Dimery, I. W., Hong, W. K. (1993) Overview of combined modality therapies for head and neck cancer. J. Natl. Cancer Inst. 85, 95–111.
Haselow, R. E., Adams, G. S.,(1983) Simultaneous cis-platinum (DDP) and radiation therapy (RT) for locally advanced unresectable head and neck cancer. Proc. ASCO 2, 160.
Weppelman, B., Wheeler, R. H.,(1991) A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 20, 357–360.
Rooney, M., Kish, J., Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hours 5-FU and cisplatin. Cancer 55, 1123–1128.
Schneider, M., Etienne, M., (1995) Phase II trial of cisplatin, fluorouracil and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J. Clin. Oncol. 13, 1656–1662.
Planting, A., Mulder, P.,(1997) Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. Eur. J. Cancer 33, 61–65.
Forastiere, A., Metch, B.,(1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol. 10, 1245–1251.
Grose, W., Lehane, D., (1985) Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat. Rep. 69, 577–581.
Taylor, S.G. IV., Murthy, A. K.,(1989) Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J. Clin. Oncol. 7, 846–856.
Department of Veteran Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced layngeal cancer. N. Engl. J. Med. 324, 1685–1690.
Lefebvre, J. L., Chevalier, D.,(1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J. Natl. Cancer Inst. 88, 890–899.
Adelstein, D., Saxton, J.,(1997) A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancers: preliminary results. Head Neck Oct. 567–575.
Taylor, S., Murthy, A.,(1994) Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J. Clin. Oncol. 12, 385–395.
Merlano, M., Vitale, V.,(1992) Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N. Engl. J. Med. 327, 1115–1121.
Shirinian, M., Weber, R.,(1994) Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the MD Anderson cancer center experience. Head Neck Jan/Feb. 39–44.
Slotman, G., Doolitle, C.,(1992) Preoperative combines chemotherapy and radiation therapy plus radical surgery in advanced head and neck cancer. Cancer 69, 2736–2743.
Vokes, E., Weichselbaum, R.,(1992) Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J. Natl. Cancer Inst. 84, 877–882.
Adelstein, D., Kalish, L., (1993) Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J. Clin. Oncol. 11, 2136–2142.
Haselow, R., Warshaw, M.,(1990) Radiation alone versus radiation with weekly low dose cis-platinum in unresectable cancer of the head and neck. Head Neck Cancer 2, 279–281.
Dragovic, J. Doyle, T.,(1995) Accelerated fractionation radiotherapy.
Trott, K., Kummermehr, J. (1985) What is known about tumour proliferation rates to choose between accelerated fractionation or hyperfractionation? Radiother. Oncol. 3, 1–9.
Forastiere, A., (1993) Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck. Semin. Oncol. 20 (Suppl 3), 55–60.
Geard, C., Jones, J.,(1994) Radiation and Taxol effects on synchronized human cervical carcinoma cell. Int. J. Radiat. Oncol. Biol. Phys. 29, 565–569.
Milas, L., Hunter, N.,(1994) Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res. 54, 3506–3510.
Forastiere, A. (1994) Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin. Oncol. 21 (5 Suppl 8), 49–52.
Vokes, E., Haraf, D.,(1995) The role of paclitaxel in the treatment of head and neck cancer. Semin. Oncol. 22 (5 Suppl 12), 8–12.
Forastiere, A., Shank, D.,(1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. Cancer 82, 2270–2274.
Castimel, G., Verweij, J.,(1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 5, 533–537.
Dreyfuss, A., Clark, J.,(1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 14, 1672–1678.
Parker, R., Dabholkar, M.,(1993) Influence of Taxol:cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc. Am. Assoc. Cancer Res. 34, 356 (abstract 2122).
Hitt, R. Paz-Ares, L. (1997) Phase I/II study of paclitaxel/cisplatin as first-line therapy for locally advanced head and neck cancer. Semin. Oncol. 24(6, Suppl 19) S19–20-S 19–24.
Forastiere, A., Leong, T., (1997) A phase III trial of high-dose paclitaxel plus cisplatin plus G-CSF versus low-dose paclitaxel plus cisplatin in patients with advanced squamous cell carcinoma of the head and neck (HNSCC): an Eastern Cooperative Oncology Group trial. Proc. Am. Soc. Clin. Oncol. 16, 1367 (abstract).
Hussain, M., Salwen, W.,(1997) Paclitaxek. cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: a preliminary report. Semin. Oncol. 24(6, Suppl. 19), S 19–43–S 19–45.
Benasso, M., Numico, G.,(1997) Chemotherapy for relapsed head and neck cancer: paclitaxek. cisplatin, and 5-fluorouracil in chemotherapy-naive patients. A dose finding-study. Semin. Oncol. 24(6 Suppl 19), S 19–46–S 19–50.
Shin, D., Glisson, B.,(1998) Phase II trial of paclitaxel, ifofamide and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16, 1325–1330.
Schoffski, P., Wanders, G.,(1996) Docetaxel and cisplatin: a highly active regimen for squamous cell carcinoma of the head and neck. Proc. ASCO 15, abstract 871.
Colevas, A., Busse, P.,(1998) Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J. Clin. Oncol. 16, 1331–1339.
Breast Cancer
Anelli, A., Albuquerque, A. A., Tabacof, J.,(1997) High response rate of paclitaxel and doxorubicin as neoadjuvant chemotherapy in locally advanced breast cancer (IIIB)preliminary results. Breast Cancer Treat. 46, 75 (abstract 313).
Antman, K., Elder, J., Elias, A., (1990) High-dose cyclophosphamide, thiotepa and carboplatin intensification with autologous bone marrow support in patients with breast cancer responding to standard dose induction therapy. Proc. ASCO. 9, 10.
Berry, J., Ezzat, A., El-Warith A., (1996) Sequential taxoUplatin:pilot in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15, abstract 243.
Bonnefoi, H. Smith, I. E., O’Brien, M. E., Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regiman. Br. J. Cancer 73 391–396.
Browne, M. J., Kennedy, T., Cummings, F. (1996) Phase II study of sequential taxol and cisplatin for the treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 15, abstract 245.
Chan, S., Friedrichs, K., Noel, D., (1997) A randomized phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an anthracycline containing regimen. Proc. ASCO 16, 154a.
Clemons, M., Leahy, M., Valle, J., (1997) Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer 33, 2183–2193.
Cocconi, G., Bisani, G., De Lisi, V., (1989). Platinum (P) and etoposide (e) as first-line chemotherapy for metastatic breast cancer (MBC). Preliminary results of a prospective randomized trial. Proc. ASCO 7, 13.
D’Andrea, G. M., and Seidman, A. D. (1997) Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin. Oncol. 24, 27–44.
Dieras, V. (1997) Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology 6, 17.
Dittrich, C., Jakesz, R., Grant, G., (1997) Preoperative paclitaxel in the first-line therapy of patients with breast cancer T 3/4, N 0–3, M 0, followed by surgery, CMF, tamoxifen and radiotherapy: Phase II trial. Proc. ASCO 16, 167.
Dombernowsky, P., (1996) Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin. Oncol. 23, 13–18.
Fernandez-Hidalgo, O., Gonzalez, F., Gil, A., (1989) 120-hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. Am. J. Clin. Oncol. 12, 397–401.
Frazier, A., Wasserheit, C., Hochster, H. (1995). High rate of peripheral neuropathy may limit paclitaxel and cisplatin combination in women with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. 14, abstract 145.
Gelmon, K. A., O’Reilly, S. E., Tolcher-A. W., (1996) Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J. Clin. Oncol. 14, 1185–1191.
a. Gradisher
Honig, S. F. (1996) Treatment of metastatic disease: hormonal therapy and chemotherapy, in Diseases of the Breast ( Harris, J. R., Lippman, M. C., Morrow, M., et al., eds.), JP Lippincott, Philadelphia, pp. 669–734.
Jones, A. L., Smith, I. E., O’Brien, M. E., (1994) Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J. Clin. Oncol. 12, 1259–1265.
Kolaric, K., Vukas, D., and Protebica, V. (1988). Combination cyclophosphamide, Adriamycin and platinum (CAP) versus 5-fluorouracil, Adriamycin and cyclophosphamide as primary treatment in metastatic breast cancer: results of a prospective randomized study. Tumori 75, 132–136.
Martin, M., Diaz-Rubio, C., Casedo, A., (1992) Carboplatin: an active drug in metastatic breast cancer. J. Clin. Oncol. 10, 433–437.
Nabbholtz, J., Thuerlimann, B., Bezwoda, W., (1977) Taxotere versus mitomycin C + vinblastine in patients with metastatic breast cancer who have failed and anthracycline containing regimen: preliminary results of a randomized phase III study. Proc. ASCO 16, 148a.
Nabholtz, J. M. (1996) Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858–1867.
O’Brien, M. D., Talbot, D. C., and Smith, I. E. (1993) Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. J. Clin. Oncol. 11, 2112–2117.
Pagani, O., Sessa, C., Martinelli, G., (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann. Oncol. 8, 655–661.
Pegram, M. D., Lipton, A., Hayes, D., (1998) Phase II study of receptor-enhanced chemosensitivity using recombinanr humanized anti-p185 HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659–2671.
Perez, E., Suman, J., Krook, P., (1988) Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast cancer (MBC): a north central cancer treatment group trial. Proc. ASCO 17, 635.
Perez, E. A., and Hartman, L. C. (1996) Paclitaxel and carboplatin for advanced breast cancer. Semin. Oncol. 23 (Suppl 11), 41–45.
Peters, W. P., Shpall, E. J., Jones, R. B., (1990) High-dose combination of cyclophosphamide (CPA), cisplatin (CDDP) and carmustine (BCNU) in bone marrow support as initial treatment for metastatic breast cancer: three-six year follow-up. Proc. ASCO 9, 10.
Radvin, P., Burris, H., Cooke, G., (1995) Phase II evaluation of docetaxel in advanced anthracycline-resistant or anthracenedione resistant breast cancer. J. Clin. Oncol. 13, 2879–2885.
Radvin, P. Valero, V., Nabholtz, J., (1996) Efficacy of a 5-day corticosteroid premedication in ameliorating Taxotere induced fluid retention. Proc. ASCO 15 124 (abstract).
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., (1991) Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9, 1692–1703.
Seidman, A. D. (1996) Chemotherapy for advanced breast cancer: a current perspective. Sem. Oncol. 23 (Suppl 2), 55–59.
Sledge, G. W. (1992) Cisplatin and platinum analogues in breast cancer. Semin. Oncol. 19, 78–82.
Sledge, G. W., Neuberg, D., Ingle, J., (1997) Phase III trial of doxorubicin (A) vs. paclitaxel vs doxorubicin + paclitaxel (A & T) as first-line therapy for metastatic breast cancer (MBC): An intergroup trial. Proc. ASCO 16, 1.
Sledge, G. W., Roth, B. J. (1989) Cisplatin in the management of breast cancer. Semin. Oncol. 16, 110–115.
ten Vokkel Huinink, W., Prove, A., Piccart, M., (1994) A phase II trial of docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann. Oncol. 5, 527.
Valero, V., Holmes, F., Walters, R., (1995) Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. 13, 2886–2894.
Vorobiof, D., Chasen, M., Moeken, R. (1996) Phase II trial of single agent docetaxel in previously treated patients with advanced breast cancer. Proc. ASCO 15, 120 (abstract).
Wasserheit, C., Frazein, A., Oratz-R, (1996) Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J. Clin. Oncol. 14, 1993–1999.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vaughan, M., Sapunar, F., Gore, M. (2000). Clinical Experience. In: Kelland, L.R., Farrell, N.P. (eds) Platinum-Based Drugs in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-012-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-59259-012-4_9
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-091-5
Online ISBN: 978-1-59259-012-4
eBook Packages: Springer Book Archive